Scholarlink

<p>Brain metastasis, a common complication of advanced non-small cell lung cancer (NSCLC), leads to poor prognosis and reduces the efficacy of immune checkpoint inhibitors (ICIs). However, the mechanisms underlying this diminished ICI response remain unclear. Here we perform single-cell RNA sequencing on 101,959 tumor-infiltrating immune cells from primary tumors and brain metastases to delineate their distinct immune landscapes. Brain metastases display profound immunosuppressive reprogramming, characterized by enrichment of HSP70-high stress-responsive T cells and PLTP⁺ tumor-associated macrophages, and depletion of memory T cells and cDC2-like dendritic cells, which show opposing associations with ICI outcomes. Integrating these findings, we derive a seven-gene brain metastasis–derived immune signature (BMIS) that is associated with ICI response and survival in NSCLC and metastatic urothelial carcinoma and provides information complementary to tumor mutational burden. These results highlight immune features specific to brain metastatic NSCLC and suggest candidate biomarkers and therapeutic avenues for improving immunotherapy in this high-risk population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of altered immune landscape at single-cell resolution in NSCLC brain metastasis and its association with poor immune checkpoint inhibitor responses

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月10日

查看全文
  • Menglin Bai,
  • Tianwen Yin,
  • Xiaohui Li,
  • Peiliang Wang,
  • Tianyu Lei,
  • Peng Jin,
  • Feng Li,
  • Hongbo Guo,
  • Xiaokang Guo,
  • Xiao Sun,
  • Yan Li,
  • Bingwen Zou,
  • Jinming Yu,
  • Chao Liu,
  • Feifei Teng

摘要

Brain metastasis, a common complication of advanced non-small cell lung cancer (NSCLC), leads to poor prognosis and reduces the efficacy of immune checkpoint inhibitors (ICIs). However, the mechanisms underlying this diminished ICI response remain unclear. Here we perform single-cell RNA sequencing on 101,959 tumor-infiltrating immune cells from primary tumors and brain metastases to delineate their distinct immune landscapes. Brain metastases display profound immunosuppressive reprogramming, characterized by enrichment of HSP70-high stress-responsive T cells and PLTP⁺ tumor-associated macrophages, and depletion of memory T cells and cDC2-like dendritic cells, which show opposing associations with ICI outcomes. Integrating these findings, we derive a seven-gene brain metastasis–derived immune signature (BMIS) that is associated with ICI response and survival in NSCLC and metastatic urothelial carcinoma and provides information complementary to tumor mutational burden. These results highlight immune features specific to brain metastatic NSCLC and suggest candidate biomarkers and therapeutic avenues for improving immunotherapy in this high-risk population.